News 30 Ene 2023 Alithea Genomics and CHUV to help make immunotherapy treatments more targeted Dutch-Swiss consortium MAINLINE, consisting of PamGene International B.V., Alithea Genomics and CHUV, received a Eurostars grant of EUR 1 million...
Aktuell 01 Mar 2024 Idorsia vereinbart Kooperation mit Viatris Das Biotech-Unternehmen Idorsia und der nordamerikanische Pharmakonzern Viatris arbeiten bei der Entwicklung zweier Phase 3-Medikamente von Ido...
News 18 Oct 2023 Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings Valais-based pharmaceutical companies Lonza and Siegfried have been recognized among the leading players in the global outsourcing landscape, wit...
Aktuell 26 Jun 2018 Global Trade Briefing: Datenbank für Handelshürden In welchem Ihrer Zielmärkte gibt es neue Regulierungen, die Ihre Exporte voranbringen oder behindern könnten? Die verbesserte Datenbank «Global T...
Evento di terzi Bridging Innovation: Unire i Tech Leader di Bergamo e Greater Zurich Area Bergamo Italy
Communiqués de Presse 08 Ago 2018 Enquête: les PME misent sur des modèles d’affaires innovants Le franc fort et la concurrence croissante pèsent sur les PME suisses. L’idée s’est imposée qu’un modèle d’affaires bien pensé est la clé d’une i...
News 06 Nov 2023 Investors stump up 3.7 million Swiss francs in Onena Medicines Onena Medicines has secured investment of 3.7 million Swiss francs. The portfolio company of the biotech start-up incubator BaseLaunch will there...
Aktuell 17 Sep 2021 Anjarium Biosciences erhält 55,5 Millionen Franken Die Anjarium Biosciences AG hat eine Serie-A-Finanzierungsrunde mit 55,5 Millionen Franken abgeschlossen. Mit dem Erlös will das Biotech-Unterneh...
Novità 02 Jun 2023 Le ultime ricerche indicano che il 20% delle aziende biotecnologiche europee ha attualmente sede in Svizzera Press release Una nuova ricerca condotta da IQVIA e pubblicata recentemente nello Swiss Biotech Report 2023 mostra che il 20% delle aziende biotecnologiche eur...
News 22 Sep 2023 TOLREMO receives 39 million US dollars in investments TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel can use this to conduc...
News 26 Mayo 2023 UCB: "It's difficult to beat Swiss quality - even the Chinese admit as much." UCB UCB is a global biopharmaceutical company based in Belgium. Since 1996, it has invested more than 600 million Swiss francs in a state-of-the-art ...
News 19 Oct 2023 Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment Biel-based Mimix Biotherapeutics announced the closure of a significant investment round, drawing participation from both European and Asian inve...
News 23 Dic 2022 Investors give Resistell 8.5 million Swiss francs Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology company plans to use this to...
News 17 Oct 2023 Voltiris, Limula, and Parithera secure Biopôle’s Start-Up Fund Vaud-based start-ups Voltiris, Limula, and Parithera gain momentum in their innovative ventures as they secure vital funding and support from Bio...
Press Release 15 Dic 2022 Swiss technology for digital worlds For the fifth time in a row, Switzerland is taking part in the Consumer Electronics Show (CES) in Las Vegas. Under the motto "swisstech for exten...
Third Party Event Digitally delivered // BioTrinity 2020 Digitally delivered Greater London United Kingdom
News 23 Ago 2023 HSLU opens microbiology analysis lab in Hergiswil Lucerne University of Applied Sciences and Arts (HSLU) has opened a microbiology analysis laboratory in Hergiswil. This will allow interdisciplin...
News 10 Oct 2023 Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million to open doors to new markets ...